Inhalation by design: Dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD
This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of ‘inhalation by design’. A key feature of this work is the combination of balanced potency and pharmacodynam...
Uložené v:
| Vydané v: | Bioorganic & medicinal chemistry letters Ročník 21; číslo 9; s. 2759 - 2763 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Amsterdam
Elsevier Ltd
01.05.2011
Elsevier |
| Predmet: | |
| ISSN: | 0960-894X, 1464-3405, 1464-3405 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Shrnutí: | This paper describes the successful design and development of dual pharmacology β-2 agonists-M3 antagonists, for the treatment of chronic obstructive pulmonary disorder using the principles of ‘inhalation by design’. A key feature of this work is the combination of balanced potency and pharmacodynamic duration with desirable pharmacokinetic and material properties, whilst keeping synthetic complexity to a minimum. |
|---|---|
| Bibliografia: | http://dx.doi.org/10.1016/j.bmcl.2010.10.132 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| ISSN: | 0960-894X 1464-3405 1464-3405 |
| DOI: | 10.1016/j.bmcl.2010.10.132 |